Published in
Springer Nature [academic journals on nature.com], Bone Marrow Transplantation, 3(55), p. 586-594, 2019
DOI: 10.1038/s41409-019-0699-6
Links
Tools
Pre-emptive rituximab treatment for Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes
Journal article published in 2019 by
Nicolas Stocker 
,
Myriam Labopin,
Inès Boussen ,
Olivier Paccoud,
Agnès Bonnin,
Florent Malard,
Corinne Amiel,
Joël Gozlan,
Giorgia Battipaglia,
Rémy Duléry ,
Federica Giannotti,
Annalisa Ruggeri,
Béatrice Gaugler,
Mohamad Mohty,
Eolia Brissot
,
Myriam Labopin,
Inès Boussen ,
Olivier Paccoud,
Agnès Bonnin,
Florent Malard,
Corinne Amiel,
Joël Gozlan,
Giorgia Battipaglia,
Rémy Duléry ,
Federica Giannotti,
Annalisa Ruggeri,
Béatrice Gaugler,
Mohamad Mohty,
Eolia Brissot
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 